Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

Biotech Beyond Borders Report finds that the biotech industry is grappling with a wave of challenges, including ongoing ...

This year marks roughly fifty years since the modern biotechnology era began — an era defined by recombinant DNA, monoclonal ...

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

As demand for advanced research capabilities grows, so too does the need for dependable sourcing, operational transparency, ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

First partnership announced under Verge Labs' platform-first model; Tenacia will apply Verge's AI platform and proprietary multimodal human tissue data to characterize targets across select CNS ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...